港股异动|药品股普涨石四药(2005.HK)升逾5%领涨
格隆汇8月21日丨药品股普涨,石四药(2005.HK)升5.33%领涨,石药集团(1093.HK)、康哲药业涨逾4%,中生制药涨逾3%,白云山、丽珠医药涨逾2%。近日,多家药企发布中期业绩公告,其中丽珠医药中期归母净利润同比增长16.67%,获交银国际升目标价至26港元;石药集团中期纯利同比增24.8%,暂连升5日累涨逾25%。此外,康哲药业皮肤线主要产品喜辽妥获纳入医保目录;白云山明日(22日)将发财报;国药控股亦将于后天发财报。板块方面,国家医保药品常规准入目录昨日挂网发布,医保局初步确定将128个药品纳入拟谈判准入范围。另据7月份私募、险企的调研情况,医药生物等行业获关注。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.